These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16610760)

  • 1. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
    Henry SP; Geary RS; Yu R; Levin AA
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.
    Iversen PL
    Curr Opin Mol Ther; 2001 Jun; 3(3):235-8. PubMed ID: 11497346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry of antisense oligonucleotides--future opportunities.
    Cook PD
    Anticancer Drug Des; 1991 Dec; 6(6):585-607. PubMed ID: 1772571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A; Iversen PL
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity.
    Ferrari N; Bergeron D; Tedeschi AL; Mangos MM; Paquet L; Renzi PM; Damha MJ
    Ann N Y Acad Sci; 2006 Oct; 1082():91-102. PubMed ID: 17145930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
    Rubenstein M; Anderson KM; Tsui P; Guinan P
    Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of second generation antisense oligonucleotides.
    Yu RZ; Grundy JS; Geary RS
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):169-82. PubMed ID: 23231725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense drug discovery and development.
    Yamamoto T; Nakatani M; Narukawa K; Obika S
    Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.
    Dirin M; Winkler J
    Expert Opin Biol Ther; 2013 Jun; 13(6):875-88. PubMed ID: 23451977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
    Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.